Intellia Therapeutics (NTLA) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free NTLA Stock Alerts $20.02 -1.15 (-5.43%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low at $19.77marketbeat.com - April 25 at 3:44 PMIntellia (NTLA) to Report Q1 Earnings: What's in the Cards?finance.yahoo.com - April 25 at 2:55 PMIntellia Therapeutics' (NTLA) "Neutral" Rating Reaffirmed at Wedbushamericanbankingnews.com - April 24 at 4:48 AMIntellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbushmarketbeat.com - April 23 at 1:49 PMFederated Hermes Inc. Increases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 20 at 6:58 AMSumitomo Mitsui Trust Holdings Inc. Sells 41,733 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 17 at 6:09 AMIntellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low at $22.51marketbeat.com - April 15 at 5:31 PMMirae Asset Global Investments Co. Ltd. Sells 100,885 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 15 at 5:17 AMCapital Advisors Inc. OK Acquires 73,379 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - April 13 at 5:00 PMCathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.fool.com - April 12 at 4:50 AMBull Market and Beyond: 3 Stocks Just Waiting to Soarfool.com - April 9 at 4:50 AMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Moderate Buy" by Analystsmarketbeat.com - April 5 at 6:36 AMIntellia Therapeutics (NASDAQ:NTLA) Shares Down 7.1% marketbeat.com - April 2 at 5:45 PMSmart Money Is Betting Big In NTLA Optionsbenzinga.com - March 28 at 8:07 PMARK Investment Management LLC Grows Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - March 28 at 6:39 AMBetter Cathie Wood Stock: Moderna vs. Intelliafool.com - March 28 at 5:55 AMIntellia Therapeutics Ends Co-Development Agreement With Regeneronmarketwatch.com - March 22 at 6:12 PMIntellia opts out of hemophilia pact with Regeneronmsn.com - March 22 at 6:12 PMHot Stocks: The 3 Best Opportunities for Investing in Biotechinvestorplace.com - March 21 at 5:29 PM3 Stocks That Could Be the Next Big Thing in Gene Editinginvestorplace.com - March 21 at 4:19 PMIntellia begins phase 3 trial for CRISPR therapy NTLA-2001investing.com - March 20 at 5:25 PMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Increased by Wellington Management Group LLPmarketbeat.com - March 19 at 4:53 AMIntellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathyglobenewswire.com - March 18 at 7:30 AMIntellia Therapeutics (NASDAQ:NTLA) Trading Down 3.6%marketbeat.com - March 12 at 1:24 PMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Analystsmarketbeat.com - March 11 at 6:17 AMIs Intellia Therapeutics Stock a Buy Now?fool.com - March 9 at 9:45 AMIntellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analystfool.com - March 6 at 10:35 AMEventide Asset Management LLC Sells 120,557 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - March 1 at 9:33 AMIntellia Therapeutics Is On The Moveseekingalpha.com - February 29 at 12:35 PMFY2024 Earnings Forecast for Intellia Therapeutics, Inc. (NASDAQ:NTLA) Issued By Cantor Fitzgeraldmarketbeat.com - February 29 at 8:41 AMA Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Nowfool.com - February 29 at 7:17 AMCathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com - February 27 at 11:55 AMAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)markets.businessinsider.com - February 26 at 3:22 PMHold Rating for Intellia Therapeutics Amid Clinical Trials and Competitive Dynamicsmarkets.businessinsider.com - February 26 at 10:22 AMBuy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial Healthmarkets.businessinsider.com - February 26 at 10:22 AMIs CRISPR Therapeutics the NVIDIA of gene editing? (NTLA)marketbeat.com - February 26 at 7:02 AMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Knowfinance.yahoo.com - February 25 at 8:36 AMIntellia Therapeutics just downgraded at Goldman Sachs, here's whyrealmoney.thestreet.com - February 24 at 9:33 AMGoldman Sachs Downgrades Intellia Therapeutics (NTLA)msn.com - February 24 at 9:33 AMCharles Schwab Investment Management Inc. Has $21.54 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)marketbeat.com - February 24 at 4:25 AMIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.8% marketbeat.com - February 23 at 2:56 PMStrong Buy Rating for Intellia Therapeutics Amid Positive Trial Updates and Robust Financial Standingmarkets.businessinsider.com - February 23 at 2:23 PMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 23 at 2:23 PMIntellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results, Beats Expectations By $0.01 EPSmarketbeat.com - February 23 at 12:53 PMIntellia Therapeutics (NASDAQ:NTLA) Given New $73.00 Price Target at Canaccord Genuity Groupmarketbeat.com - February 23 at 10:17 AMIntellia Therapeutics (NASDAQ:NTLA) Lowered to "Neutral" at The Goldman Sachs Groupmarketbeat.com - February 23 at 9:43 AMIntellia Therapeutics: Hold Rating Maintained Amid Fair Valuation and Anticipated Clinical Milestonesmarkets.businessinsider.com - February 23 at 8:45 AMIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Federated Hermes Inc.marketbeat.com - February 23 at 8:38 AMQ4 2023 Intellia Therapeutics Inc Earnings Callfinance.yahoo.com - February 22 at 11:16 PMIntellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progressfinance.yahoo.com - February 22 at 8:14 AM Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy NTLA Media Mentions By Week NTLA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.140.37▲Average Medical News Sentiment NTLA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼64▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Celldex Therapeutics News Myriad Genetics News Neogen News QuidelOrtho News Editas Medicine News Cellectis News Sangamo Therapeutics News Lantheus News Beam Therapeutics News Privia Health Group News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
